Fig. 8.

SB-239063 inhibition of aglycemia-, OGD-, and AVP-stimulated CMEC Na-K-Cl cotransporter activity. CMEC monolayers were pretreated for 30 min with SB-239063 (20 μM) or vehicle and then exposed for 30–120 min to normoxic control (19% O₂ in HEPES-DMEM), aglycemia (A, glucose- and pyruvate-free HEPES-DMEM), OGD (B, aglycemia at 2% O₂), or AVP (C, 100 nM, in normoxic HEPES-DMEM) and SB-239063 or vehicle. CMEC Na-K-Cl cotransporter activity was assessed as ouabain-insensitive, bumetanide-sensitive K influx. Pretreatment conditions were maintained throughout the assay. Values are means ± SE for 6, 8, and 9 separate experiments for aglycemia, OGD, and AVP, respectively. *Significantly different (vehicle vs. SB-239063), P < 0.05 by repeated-measures ANOVA with Tukey's post hoc test. Vehicle values for ischemic factors are significantly different from vehicle control at 30, 60, 90, and 120 min (A and B) and at 30, 60, and 120 min (C), P < 0.05 by 1-tailed paired t-test.